Skip to content

What are the factors affecting gastroretentive drug delivery system?

5 min read

According to a review in Current State and Future Perspectives on Gastroretentive Drug Delivery Systems, multiple factors influence gastric retention time (GRT), a key determinant for the success of any gastroretentive drug delivery system (GRDDS). These systems are engineered to remain in the stomach for an extended period, requiring a nuanced understanding of numerous interacting variables to be effective.

Quick Summary

The performance of gastroretentive drug delivery systems is influenced by pharmaceutical factors like dosage form properties, physiological conditions such as feeding state, and patient variables like age and health status. Optimizing these systems requires considering multiple interconnected factors for effective drug delivery.

Key Points

  • Pharmaceutical Properties: Dosage form density, size, and shape are critical for achieving and maintaining gastric retention, influencing mechanisms like floating, sinking, and swelling.

  • Formulation Composition: The selection and characteristics of polymers and excipients, such as swelling properties or gas-generating capabilities, directly impact the GRDDS's performance.

  • Feeding State: The fed state significantly prolongs gastric residence time by interrupting the Migrating Myoelectric Complex (MMC), a key physiological factor.

  • Meal Characteristics: High-calorie, high-fat, high-protein, or viscous meals can increase the residence time of GRDDS compared to a fasted state.

  • Patient-Specific Variables: Factors such as age, gender, underlying disease states (like diabetes or Parkinson's), and even emotional state can cause significant individual variability in gastric emptying.

  • Drug Properties: The drug's solubility and stability in the acidic gastric environment are crucial; GRDDS are unsuitable for drugs that irritate the stomach lining or are unstable at low pH.

  • Concurrent Medications: Other drugs, like anticholinergics or opiates, can alter gastrointestinal motility and affect the GRT of the GRDDS.

In This Article

A gastroretentive drug delivery system (GRDDS) is a specialized oral dosage form designed to prolong the residence time of a drug in the stomach. This extended stay is crucial for drugs that are primarily absorbed in the upper gastrointestinal tract, have a narrow absorption window, or benefit from local action in the stomach, such as certain antibiotics for H. pylori infections. However, the efficacy of a GRDDS is not guaranteed and depends on a complex interplay of pharmaceutical, physiological, and patient-specific factors. A thorough understanding of these variables is necessary for the successful development and application of GRDDS.

Pharmaceutical Factors Affecting GRDDS

These are the factors directly related to the design and composition of the dosage form. They are controllable during the manufacturing process and are engineered to facilitate the gastric retention mechanism.

Dosage Form Properties

  • Density: For floating systems, the dosage form's density must be less than that of gastric fluid (approximately 1.004 g/cm³) to remain buoyant. High-density systems, in contrast, must have a density greater than 2.5 g/cm³ to sink to the bottom of the stomach and resist peristalsis.
  • Size and Shape: The physical dimensions of the dosage form are critical. Systems larger than 7.5 mm in diameter generally exhibit longer gastric residence times, as they are too large to pass through the pyloric sphincter during the fasting state's migrating myoelectric complex (MMC). Expandable systems, or "plug-type" systems, are designed to swell to a size exceeding the pyloric diameter, effectively blocking their passage. The shape can also matter, with certain geometries like ring or tetrahedron shapes showing longer retention times.
  • Single vs. Multiple Units: Multi-unit formulations (e.g., microparticles, pellets) offer a more predictable drug release profile and a greater margin of safety if some individual units fail. Single-unit systems (e.g., tablets, capsules) can be less reliable if they fail to perform their retention mechanism correctly.

Formulation and Excipients

  • Polymer Type: The choice of polymer is fundamental to the GRDDS mechanism. Polymers like hydroxypropyl methylcellulose (HPMC) and polyethylene oxide (PEO) are used in swelling and floating systems. Bioadhesive or mucoadhesive polymers, such as Carbopol and chitosan, are employed to adhere the dosage form to the gastric mucosa, prolonging its residence.
  • Polymer Properties: The molecular weight, viscosity, and hydration level of the polymer influence its performance. A balanced degree of cross-linking in swelling polymers is necessary; too little can cause rapid dissolution, while too much can hinder sufficient swelling.
  • Gas-Generating Agents: In effervescent floating systems, agents like sodium bicarbonate and citric acid are included to generate carbon dioxide gas, which facilitates buoyancy. The concentration and ratio of these agents affect the floating lag time and duration.

Drug-Related Properties

  • Solubility: The drug's solubility profile is a major consideration. GRDDS are ideal for drugs that are more soluble in the acidic gastric environment but become poorly soluble at the higher pH of the intestine. Conversely, drugs that are unstable in acid or poorly soluble in gastric fluid are unsuitable.
  • Stability: The chemical stability of the drug within the harsh, acidic environment of the stomach must be considered. Some drugs may degrade if exposed to gastric acid for prolonged periods.

Physiological and External Factors

The dynamic nature of the gastrointestinal tract means that many physiological and external variables can impact the performance of a GRDDS.

Fed vs. Fasted State

  • Fasting: In a fasting state, the stomach exhibits a periodic cyclic activity known as the Migrating Myoelectric Complex (MMC). The MMC's intense housekeeping wave can sweep the dosage form out of the stomach and into the small intestine, potentially resulting in a very short GRT if the system is administered at the wrong time.
  • Fed State: The presence of food interrupts the MMC and delays gastric emptying. Administering a GRDDS with a meal, particularly a high-fat or high-protein one, can significantly prolong its gastric residence time.

Nature and Caloric Content of Meals

  • Food Composition: The specific components of a meal play a role. High-fat, high-protein, and fiber-rich meals can delay gastric emptying more effectively than low-calorie meals.
  • Meal Viscosity: A high-viscosity meal can also contribute to a longer GRT.
  • Meal Frequency: Frequent, smaller meals tend to extend gastric retention compared to a single large meal due to sustained inhibition of the MMC.

Posture and Physical Activity

  • Posture: A patient's posture can affect GRT. In an upright position, floating systems work optimally as they remain at the top of the gastric fluid. In a supine (lying down) position, non-floating systems may experience longer retention.
  • Physical Activity: Increased physical activity can alter gastric motility and affect the predictability of GRT.

Patient-Specific Variables

Individual patient characteristics introduce significant variability that can influence GRDDS performance.

Age and Gender

  • Age: Gastric emptying time tends to be slower in the elderly (over 70) compared to younger patients. This can result in longer GRT, which may require dose adjustment.
  • Gender: Studies have shown that females often have a slower gastric emptying time than males, irrespective of other physical factors. This variation is thought to be influenced by hormonal fluctuations.

Disease States and Emotional Condition

  • Disease: Certain medical conditions, such as gastroparesis in diabetic patients or delayed motility in Parkinson's disease, significantly prolong GRT. Conversely, some GI disorders may accelerate emptying.
  • Emotional State: Emotional states like stress or anxiety can alter GI motility. Anxiety can increase the rate of gastric emptying, while depression may decrease it.

Concurrent Medications

  • The co-administration of other drugs can interfere with a GRDDS. For example, anticholinergic agents (like atropine) and opiates are known to slow gastric emptying, while prokinetic agents accelerate it. This needs to be considered when prescribing other medications.

Comparison of Key Gastroretentive Mechanisms

Mechanism Principle Key Materials Advantages Disadvantages
Floating Systems Low density allows buoyancy on gastric contents. Hydrophilic polymers (HPMC, PEO), effervescent agents (sodium bicarbonate). Simple, low cost, widely used, predictable release. Requires sufficient gastric fluid, influenced by posture, potential for esophageal reflux.
Mucoadhesive Systems Adhesion to the stomach's mucosal lining for retention. Mucoadhesive polymers (Carbopol, Chitosan, Sodium Alginate). Site-specific delivery, less dependent on fed state. Mucin turnover can be unpredictable, adherence can be inconsistent.
Expandable Systems Swells to a large size after ingestion, preventing passage through the pylorus. Highly swellable polymers (HPMC, PEO, Hydrogels). Very long GRT, sustained release. Potential for gastric obstruction, complex to manufacture, sensitive to hydration levels.
High-Density Systems Density > 2.5 g/cm³ causes sinking and retention in the stomach's antral region. Heavy materials (barium sulfate, iron powder). Reliable retention regardless of fed state. High material cost, potential for dose dumping, complex formulation.

Conclusion

The success of a gastroretentive drug delivery system is dependent on managing a complex set of interacting variables. The ideal system results from a precise balance of pharmaceutical, physiological, and patient-specific factors. Formulation design must consider not only the physical and chemical properties of the dosage form—like its density, size, and excipients—but also the drug's inherent characteristics. Furthermore, the dynamic physiological environment of the stomach, heavily influenced by meals and gastric motility, and individual patient variables, such as age and health status, introduce significant complexities that must be accounted for. While promising, the inherent variability of these factors highlights the need for continued innovation in GRDDS design, such as personalized dosage forms and smart materials, to ensure reliable and predictable therapeutic outcomes.

Further Reading

Frequently Asked Questions

A GRDDS is a type of oral drug formulation engineered to remain in the stomach for an extended period, allowing for a sustained and controlled drug release to improve therapeutic efficacy, especially for drugs with a limited absorption window in the upper GI tract.

The fed state delays gastric emptying by inhibiting the Migrating Myoelectric Complex (MMC). This allows a GRDDS, particularly floating or expandable systems, to remain in the stomach for a longer duration, providing more predictable and extended drug release.

Size is crucial because the pyloric sphincter acts as a filter. Dosage forms that swell to a size larger than the sphincter's diameter (typically >15 mm) in their expanded state can be physically retained in the stomach, preventing premature emptying.

Yes, high-density systems work by sinking to the bottom of the stomach, where they can be retained longer than less dense materials. Their density must be greater than 2.5 g/cm³ to effectively resist gastric contractions and remain in the antral region.

Patient factors like age, gender, and disease states introduce significant variability. The elderly and females, for example, often have longer gastric emptying times, while conditions like diabetes or Parkinson's can also affect motility.

No, GRDDS are not suitable for all drugs. They are inappropriate for drugs that cause gastric irritation, are unstable in acidic environments, or are meant for targeted release further down the GI tract.

The main types of GRDDS include floating systems (low density), mucoadhesive systems, expandable or swelling systems, and high-density systems. Each type uses a distinct mechanism to achieve gastric retention.

References

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

Medical Disclaimer

This content is for informational purposes only and should not replace professional medical advice.